ClinicalTrials.gg
Active, not recruitingNCT04579380Updated Aug 21, 2026Results posted

Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations

A Phase 2 interventional study of tucatinib and trastuzumab in Uterine Neoplasms, Uterine Cervical Neoplasms and Biliary Tract Neoplasms, sponsored by Seagen, a wholly owned subsidiary of Pfizer. Active, not recruiting at 108 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-21.

Primary conditionUterine Cervical NeoplasmsRegistry: Uterine NeoplasmsReclassifiedWhy we changed it
Registry
Uterine Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Uterine Cervical Neoplasms
Why
  1. The study's listed conditions name Uterine Cervical Neoplasms, a narrower term within Uterine Neoplasms.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Seagen, a wholly owned subsidiary of Pfizer (part of Pfizer) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
217
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies in Uterine Cervical Neoplasms by Pfizer — 3 open to participants now, 4 under way, none of them phase 3. Uterine Cervical Neoplasms · Pfizer.

Enrollment
3rd of 16
217 · median 122
Started
2021
with 2 others
Phase 2
4 of 17
none open now
Registered
11th of 17
by date

Among the 17 studies in Uterine Cervical Neoplasms by Pfizer, this one is the 3rd largest by enrollment of the 16 interventional ones that give a count, is one of 3 that started in 2021, is one of 4 in phase 2, and was the 11th registered.

Uterine Cervical Neoplasms

2,368 studies on the registry are indexed under Uterine Cervical Neoplasms; 678 are open to participants now.

Browse Uterine Cervical Neoplasms studies →

Open to participants now

3 of the 17 studies in Uterine Cervical Neoplasms by Pfizer are open now, in 8 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 474 Uterine Cervical Neoplasms studies recruiting now, 244 (51%) set no upper age limit and 190 (40%) stop at 75 or younger; 20 take children under 18; 68 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Uterine Cervical Neoplasms by Pfizer, or all of them as a file.
02

Study summary

This trial studies how well tucatinib works for solid tumors that make either more HER2 or a different type of HER2 than usual (HER2 alterations) The solid tumors studied in this trial have either spread to other parts of the body (metastatic) or cannot be removed completely with surgery (unresectable).

All participants will get both tucatinib and trastuzumab. People with hormone-receptor positive breast cancer will also get a drug called fulvestrant.

The trial will also look at what side effects happen. A side effect is anything a drug does besides treating cancer.

Read the detailed description

There are multiple cohorts in this trial:

  • 5 tumor specific cohorts with HER2 overexpression/amplification (cervical cancer, uterine cancer, biliary tract cancer, urothelial cancer, and non-squamous non-small cell lung cancer [NSCLC])
  • 2 tumor specific cohorts with HER2 mutations (non-squamous NSCLC and breast cancer)
  • 2 cohorts which will enroll all other HER2 amplified/overexpressed solid tumor types (except breast cancer, gastric or gastroesophageal junction adenocarcinoma [GEC], and colorectal cancer [CRC]) or HER2-mutated solid tumor types.
03

Conditions studied

  • Uterine Neoplasms
  • Uterine Cervical Neoplasms
  • Biliary Tract Neoplasms
  • Urologic Neoplasms
  • Carcinoma, Non-Small-Cell Lung
  • HER2 Mutations Breast Neoplasms

Keywords

  • Cervical cancer
  • Uterine cancer
  • Biliary tract cancer
  • Urothelial cancer
  • Non-squamous non-small cell lung cancer
  • Non-squamous NSCLC
  • Breast cancer
  • Colorectal cancer
  • Ampullary cancer
  • Solid tumors
  • Solid tumors harboring somatic HER2 mutations
  • Seattle Genetics
04

In context

Uterine Cervical Neoplasms Reclassified

2,368 studies on the registry are indexed under Uterine Cervical Neoplasms; 678 are open to participants now.

This study's enrollment of 217 is above the median of 100 across 1,739 interventional studies indexed under Uterine Cervical Neoplasms.

Browse Uterine Cervical Neoplasms studies →

Lead sponsor

Seagen, a wholly owned subsidiary of Pfizer is the lead sponsor of 30 studies on the registry; 4 are open to participants now.

Of its 11 completed or terminated interventional studies of FDA-regulated products, 3 (27%) have results posted.

First submitted before Seagen Inc. became part of Pfizer.

Compared within Uterine Cervical Neoplasms, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Uterine Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically confirmed diagnosis of locally-advanced unresectable or solid tumor, including primary brain tumors
  • Participants with non-squamous NSCLC must have progressed during or after standard treatment or for which no standard treatment is available
  • Participants with other disease types must have progressed during or after ≥1 for locally-advanced unresectable or metastatic disease
  • Disease progression during or after, or intolerance of, the most recent line of systemic therapy
  • Disease demonstrating alterations (overexpression/amplification or HER2 activating mutations), as determined by local or central testing processed in a Clinical Laboratory Improvement Amendments (CLIA)- or International Organization for Standardization (ISO) accredited laboratory, according to one of the following:

    • HER2 overexpression/amplification from fresh or or blood
    • Known activating HER2 mutations detected in fresh or archival tumor tissue or blood
  • Have per v1.1 criteria according to investigator assessment
  • Have (ECOG) performance status 0 or 1

Exclusion criteria

Exclusion Criteria

  • Participants with breast cancer, gastric or gastroesophageal junction adenocarcinoma, or CRC whose disease shows amplification/overexpression.
  • Previous treatment with HER2-directed therapy; participants with uterine serous carcinoma or HER2-mutated gastric or gastroesophageal junction adenocarcinoma without HER2-overexpression/amplification may have received prior trastuzumab
  • Known to any component of the drug formulation of tucatinib or trastuzumab (drug substance, , murine proteins), or any component of the drug formulation of fulvestrant in participants with HR+ HER2-mutated breast cancer
  • History of exposure to a 360 mg/m² doxorubicin-equivalent or >720 mg/m\^2 epirubicin-equivalent cumulative dose of anthracyclines
  • Treatment with any systemic anti-cancer therapy, radiation therapy, major surgery, or experimental agent within ≤3 weeks of first dose of study treatment or are currently participating in another interventional clinical trial.

There are additional inclusion and exclusion criteria. The study center will determine if criteria for participation are met.

Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
217 participants (actual)

Study arms

  • Experimental
    Tucatinib + Trastuzumab (+ Fulvestrant)

    Tucatinib + trastuzumab (+ fulvestrant in hormone-receptor positive HER2-mutant breast cancer only)

    Drug: tucatinib · Drug: trastuzumab · Drug: fulvestrant

Interventions

  • 300 mg orally twice daily

    Also known as: TUKYSA, ARRY-380, ONT-380

  • Given into the vein (intravenously; IV). 8mg/kg IV on Cycle 1 Day 1, and 6mg/kg every 21 days starting on Cycle 2 Day 1

    Also known as: Herceptin

  • Given into the muscle (intramuscular; IM) once every 4 weeks starting from Cycle 1 Day 1, plus one dose on Cycle 1 Day 15. Only administered to participants with hormone-receptor positive breast cancer.

    Also known as: Faslodex

07

What researchers measure

Primary outcomes

  1. Confirmed Objective Response Rate (cORR) as Assessed by Investigator

    Confirmed ORR was defined as the percentage of participants with best overall response of complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria version (v)1.1 as assessed by investigator and was considered as confirmed when subsequent response was at least 4 weeks after initial response. As per RECIST v1.1, CR: disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<)10 millimeter (mm). PR: at least a greater than or equal to (\>=)30 % decrease in the sum of diameters (SOD) of target lesions (longest for non-nodal target lesions and the short axes for nodal target lesions), taking as reference the baseline sum diameters. Disease progression (PD): at least \>=20% relative increase in SOD of target lesion taking as reference the smallest sum on study (including baseline sum if that is the smallest on study).

    Time frame: From the first dose of study treatment until the first documented CR or PR on or before the first documented PD or new anti-cancer therapies or death, whichever occurred first (up to 28.3 months)

Secondary outcomes

  1. Confirmed Disease Control Rate (DCR) as Assessed by Investigator

    DCR was defined as the percentage of participants with confirmed CR, PR, or stable disease (SD or non-CR/non-PD) according to RECIST v1.1 as assessed by investigator. As per RECIST v1.1, CR: disappearance of all target (T) lesions and non-target (NT) lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR: at least \>=30 % decrease in the SOD of target lesions (longest for non-nodal target lesions and the short axes for nodal target lesions), taking as reference the baseline sum diameters. PD: at least \>=20% relative increase in SOD of target lesions taking as reference the smallest sum on study (including baseline sum if that is the smallest on study). SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest SOD while on study and cannot have met criteria for PD previously.

    Time frame: From the first dose study treatment until PD or death, whichever occurred first (approximately 52.7 months)

  2. Duration of Response (DOR) as Assessed by Investigator

    DOR: time from first documentation of confirmed CR/PR to first documentation of PD according to RECIST v1.1 or death from any cause, whichever occurred earlier. Per RECIST v1.1, CR: disappearance of all T/NT lesions(L). Any pathological lymph nodes (whether T/NT) must have reduction in short axis to \<10 mm. PR: at least \>=30 % decrease in SOD of TL, taking reference baseline sum diameters. PD: at least \>=20% relative increase in SOD of TL taking reference smallest sum on study. Participants who do not have PD \& were still on study at time of an analysis/ who have started new anticancer treatment/discontinue prior to documentation of PD were censored at date of last adequate response assessment documenting absence of PD. Participants who had PD/death occurred after two/more consecutive missing scheduled response assessments were censored at date of last adequate response assessment of CR, PR, SD,/non-CR/non-PD. Kaplan-Meier method was used for evaluation.

    Time frame: From the first documented CR or PR until the first documentation of PD or death or censoring date, whichever occurred first (approximately 52.7 months)

  3. Progression-Free Survival (PFS) as Assessed by Investigator

    PFS was defined as time from the date of treatment initiation to date of PD as per RECIST v1.1 or death from any cause, whichever occurred first . As per RECIST v1.1, PD: least \>=20% relative increase in SOD of target lesions taking as reference the smallest sum on study (including baseline sum if that is smallest on study). Participants who do not have PD and were still on study at time of an analysis/ who have started new anticancer treatment/discontinue prior to documentation of PD were censored at date of last adequate response assessment documenting absence of PD. Participants who had PD or death occurred after two or more consecutive missing scheduled response assessments were censored at date of last adequate response assessment of CR, PR, SD,/non-CR/non-PD. Kaplan-Meier method was used for evaluation.

    Time frame: From the first documented CR or PR until the first documentation of PD or death or censoring date, whichever occurred first (approximately 52.7 months)

  4. Overall Survival (OS)

    OS was defined as the time from treatment initiation to death due to any cause. For a participant who was not known to have died by the end of study follow-up, observation of OS was censored on the date the participant was last known to be alive (i.e., the date of last contact). Participants lacking data beyond the day of treatment initiation were censored on the date of treatment initiation (i.e., OS duration of 1 day). Kaplan-Meier method was used for evaluation.

    Time frame: From date of start of study treatment until date of death or censoring date (approximately 52.7 months)

  5. Number of Participants With Treatment Emergent Adverse Events (TEAEs)

    An AE was any untoward medical occurrence in a participant or clinical investigational participant administered a medicinal product and which did not necessarily have a causal relationship with this treatment. A TEAE was defined as a newly occurring or worsening AE after the first dose of study treatment.

    Time frame: From first dose of the study treatment (Day 1) up to 30 days after the last dose of study treatment (approximately 52.7 months)

  6. Number of Participants With Treatment Emergent Laboratory Test Abnormalities

    Treatment-emergent laboratory abnormalities were defined as abnormalities that are new or worsened on or after receiving the first dose of study treatment up to 30 days after the last dose of study treatment. The following laboratory abnormalities were assessed: A-) Hematology: hemoglobin decreased, leukocytes decreased, lymphocytes decreased and increased, neutrophils decreased and platelets decreased; B-) Chemistry: alanine aminotransferase increased, albumin decreased, alkaline phosphatase increased, aspartate aminotransferase increased, calcium corrected for albumin decreased and increased, creatinine increased, glomerular filtration rate estimated decreased, glucose decreased, lactate dehydrogenase increased, magnesium increased and decreased, potassium increased and decreased, sodium increased and decreased and total bilirubin increased.

    Time frame: From first dose of the study treatment (Day 1) up to 30 days after the last dose of study treatment (approximately 52.7 months)

  7. Number of Participants With Any Dose Modifications Due to AEs

    Dose modification included dose hold, dose reduction, or discontinuation of drugs. Dose reductions or treatment interruption/discontinuation were made at the discretion of the investigator.

    Time frame: From first dose of the study treatment (Day 1) up to the last dose of study treatment (approximately 52.7 months)

  8. Number of Participants With TEAEs of Special Interest

    An adverse event of special interest (AESI) were any serious or nonserious AE that were of scientific or medical concern as defined by the sponsor and specific to the program, for which ongoing monitoring and rapid communication to the sponsor were appropriate. A TEAE was defined as a newly occurring or worsening AE after the first dose of study treatment (tucatinib, trastuzumab or fulvestrant). AESIs for this study were related to hepatoxicity.

    Time frame: From first dose of the study treatment (Day 1) up to the last dose of study treatment (approximately 52.7 months)

  9. Maximum Concentration (Cmax) of Tucatinib

    Time frame: Cycle 3 Day 1: anytime within 1-4 hours post-dose

  10. Trough Concentration (Ctrough) of Tucatinib

    Time frame: Cycle 3 Day 1: Predose

08

Results

Posted Nov 13, 2024

Participant flow

Participants with locally-advanced (LA) unresectable or metastatic solid tumors driven by human epidermal growth factor receptor 2 (HER2) alterations, who were previously treated, were enrolled to receive tucatinib in combination with trastuzumab in this study. Participants with hormone-receptor positive breast cancer also received fulvestrant.

Participant flow — Overall Study
MilestoneTucatinib+Trastuzumab (Cohort 1)Tucatinib+Trastuzumab (Cohort 2)Tucatinib+Trastuzumab (Cohort 3)Tucatinib+Trastuzumab (Cohort 4)Tucatinib+Trastuzumab (Cohort 5)Tucatinib+Trastuzumab (Cohort 6)Tucatinib+Trastuzumab (Cohort 7)Tucatinib+Trastuzumab+ Fulvestrant (Cohort 8)Tucatinib+Trastuzumab (Cohort 9)
Started113130251231133133
Completed000000000
Not completed113130251231133133
Withdrew: Death9222217621101125
Withdrew: Withdrawal by subject034012012
Withdrew: Ongoing2648583196

Outcome measures

PrimaryConfirmed Objective Response Rate (cORR) as Assessed by Investigator

Confirmed ORR was defined as the percentage of participants with best overall response of complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria version (v)1.1 as assessed by investigator and was considered as confirmed when subsequent response was at least 4 weeks after initial response. As per RECIST v1.1, CR: disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<)10 millimeter (mm). PR: at least a greater than or equal to (\>=)30 % decrease in the sum of diameters (SOD) of target lesions (longest for non-nodal target lesions and the short axes for nodal target lesions), taking as reference the baseline sum diameters. Disease progression (PD): at least \>=20% relative increase in SOD of target lesion taking as reference the smallest sum on study (including baseline sum if that is the smallest on study).

Time frame:
From the first dose of study treatment until the first documented CR or PR on or before the first documented PD or new anti-cancer therapies or death, whichever occurred first (up to 28.3 months)
Reported as:
Number · Percentage of participants
Confirmed Objective Response Rate (cORR) as Assessed by Investigator
Percentage of participantsTucatinib+Trastuzumab (Cohort 1)Tucatinib+Trastuzumab (Cohort 2)Tucatinib+Trastuzumab (Cohort 3)Tucatinib+Trastuzumab (Cohort 4)Tucatinib+Trastuzumab (Cohort 5)Tucatinib+Trastuzumab (Cohort 6)Tucatinib+Trastuzumab (Cohort 7)Tucatinib+Trastuzumab+ Fulvestrant (Cohort 8)Tucatinib+Trastuzumab (Cohort 9)
Confirmed Objective Response Rate (cORR) as Assessed by Investigator27.3 (7.9 to 56.4)13.3 (4.7 to 28.0)46.7 (30.8 to 63.0)8.0 (1.4 to 23.1)8.3 (0.4 to 33.9)22.6 (11.1 to 38.3)0 (0.0 to 20.6)41.9 (26.9 to 58.2)10.3 (2.9 to 24.6)
SecondaryConfirmed Disease Control Rate (DCR) as Assessed by Investigator

DCR was defined as the percentage of participants with confirmed CR, PR, or stable disease (SD or non-CR/non-PD) according to RECIST v1.1 as assessed by investigator. As per RECIST v1.1, CR: disappearance of all target (T) lesions and non-target (NT) lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR: at least \>=30 % decrease in the SOD of target lesions (longest for non-nodal target lesions and the short axes for nodal target lesions), taking as reference the baseline sum diameters. PD: at least \>=20% relative increase in SOD of target lesions taking as reference the smallest sum on study (including baseline sum if that is the smallest on study). SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest SOD while on study and cannot have met criteria for PD previously.

Time frame:
From the first dose study treatment until PD or death, whichever occurred first (approximately 52.7 months)

Results for this outcome have not been posted.

SecondaryDuration of Response (DOR) as Assessed by Investigator

DOR: time from first documentation of confirmed CR/PR to first documentation of PD according to RECIST v1.1 or death from any cause, whichever occurred earlier. Per RECIST v1.1, CR: disappearance of all T/NT lesions(L). Any pathological lymph nodes (whether T/NT) must have reduction in short axis to \<10 mm. PR: at least \>=30 % decrease in SOD of TL, taking reference baseline sum diameters. PD: at least \>=20% relative increase in SOD of TL taking reference smallest sum on study. Participants who do not have PD \& were still on study at time of an analysis/ who have started new anticancer treatment/discontinue prior to documentation of PD were censored at date of last adequate response assessment documenting absence of PD. Participants who had PD/death occurred after two/more consecutive missing scheduled response assessments were censored at date of last adequate response assessment of CR, PR, SD,/non-CR/non-PD. Kaplan-Meier method was used for evaluation.

Time frame:
From the first documented CR or PR until the first documentation of PD or death or censoring date, whichever occurred first (approximately 52.7 months)

Results for this outcome have not been posted.

SecondaryProgression-Free Survival (PFS) as Assessed by Investigator

PFS was defined as time from the date of treatment initiation to date of PD as per RECIST v1.1 or death from any cause, whichever occurred first . As per RECIST v1.1, PD: least \>=20% relative increase in SOD of target lesions taking as reference the smallest sum on study (including baseline sum if that is smallest on study). Participants who do not have PD and were still on study at time of an analysis/ who have started new anticancer treatment/discontinue prior to documentation of PD were censored at date of last adequate response assessment documenting absence of PD. Participants who had PD or death occurred after two or more consecutive missing scheduled response assessments were censored at date of last adequate response assessment of CR, PR, SD,/non-CR/non-PD. Kaplan-Meier method was used for evaluation.

Time frame:
From the first documented CR or PR until the first documentation of PD or death or censoring date, whichever occurred first (approximately 52.7 months)

Results for this outcome have not been posted.

SecondaryOverall Survival (OS)

OS was defined as the time from treatment initiation to death due to any cause. For a participant who was not known to have died by the end of study follow-up, observation of OS was censored on the date the participant was last known to be alive (i.e., the date of last contact). Participants lacking data beyond the day of treatment initiation were censored on the date of treatment initiation (i.e., OS duration of 1 day). Kaplan-Meier method was used for evaluation.

Time frame:
From date of start of study treatment until date of death or censoring date (approximately 52.7 months)

Results for this outcome have not been posted.

SecondaryNumber of Participants With Treatment Emergent Adverse Events (TEAEs)

An AE was any untoward medical occurrence in a participant or clinical investigational participant administered a medicinal product and which did not necessarily have a causal relationship with this treatment. A TEAE was defined as a newly occurring or worsening AE after the first dose of study treatment.

Time frame:
From first dose of the study treatment (Day 1) up to 30 days after the last dose of study treatment (approximately 52.7 months)

Results for this outcome have not been posted.

SecondaryNumber of Participants With Treatment Emergent Laboratory Test Abnormalities

Treatment-emergent laboratory abnormalities were defined as abnormalities that are new or worsened on or after receiving the first dose of study treatment up to 30 days after the last dose of study treatment. The following laboratory abnormalities were assessed: A-) Hematology: hemoglobin decreased, leukocytes decreased, lymphocytes decreased and increased, neutrophils decreased and platelets decreased; B-) Chemistry: alanine aminotransferase increased, albumin decreased, alkaline phosphatase increased, aspartate aminotransferase increased, calcium corrected for albumin decreased and increased, creatinine increased, glomerular filtration rate estimated decreased, glucose decreased, lactate dehydrogenase increased, magnesium increased and decreased, potassium increased and decreased, sodium increased and decreased and total bilirubin increased.

Time frame:
From first dose of the study treatment (Day 1) up to 30 days after the last dose of study treatment (approximately 52.7 months)

Results for this outcome have not been posted.

SecondaryNumber of Participants With Any Dose Modifications Due to AEs

Dose modification included dose hold, dose reduction, or discontinuation of drugs. Dose reductions or treatment interruption/discontinuation were made at the discretion of the investigator.

Time frame:
From first dose of the study treatment (Day 1) up to the last dose of study treatment (approximately 52.7 months)

Results for this outcome have not been posted.

SecondaryNumber of Participants With TEAEs of Special Interest

An adverse event of special interest (AESI) were any serious or nonserious AE that were of scientific or medical concern as defined by the sponsor and specific to the program, for which ongoing monitoring and rapid communication to the sponsor were appropriate. A TEAE was defined as a newly occurring or worsening AE after the first dose of study treatment (tucatinib, trastuzumab or fulvestrant). AESIs for this study were related to hepatoxicity.

Time frame:
From first dose of the study treatment (Day 1) up to the last dose of study treatment (approximately 52.7 months)

Results for this outcome have not been posted.

SecondaryMaximum Concentration (Cmax) of Tucatinib
Time frame:
Cycle 3 Day 1: anytime within 1-4 hours post-dose
Reported as:
Geometric mean · Nanogram per milliliter
Maximum Concentration (Cmax) of Tucatinib
Nanogram per milliliterTucatinib+Trastuzumab (Cohort 1)Tucatinib+Trastuzumab (Cohort 2)Tucatinib+Trastuzumab (Cohort 3)Tucatinib+Trastuzumab (Cohort 4)Tucatinib+Trastuzumab (Cohort 5)Tucatinib+Trastuzumab (Cohort 6)Tucatinib+Trastuzumab (Cohort 7)Tucatinib+Trastuzumab+ Fulvestrant (Cohort 8)Tucatinib+Trastuzumab (Cohort 9)
Maximum Concentration (Cmax) of Tucatinib488.2 ± 104.9483.1 ± 53.5319.2 ± 116.2275.9 ± 122.8437.2 ± 60.0330.4 ± 164.2207.7 ± 344.6393.2 ± 255.6242.9 ± 155.1
SecondaryTrough Concentration (Ctrough) of Tucatinib
Time frame:
Cycle 3 Day 1: Predose
Reported as:
Geometric mean · Nanogram per milliliter
Trough Concentration (Ctrough) of Tucatinib
Nanogram per milliliterTucatinib+Trastuzumab (Cohort 1)Tucatinib+Trastuzumab (Cohort 2)Tucatinib+Trastuzumab (Cohort 3)Tucatinib+Trastuzumab (Cohort 4)Tucatinib+Trastuzumab (Cohort 5)Tucatinib+Trastuzumab (Cohort 6)Tucatinib+Trastuzumab (Cohort 7)Tucatinib+Trastuzumab+ Fulvestrant (Cohort 8)Tucatinib+Trastuzumab (Cohort 9)
Trough Concentration (Ctrough) of Tucatinib196.6 ± 100.199.9 ± 482.9145.7 ± 383.0105.1 ± 355.146.5 ± 3312.4115.4 ± 328.3267.4 ± 165.2126.9 ± 234.5142.3 ± 184.1

Adverse events

Collected over From first dose of the study treatment (Day 1) maximum up to 30 days after the last dose of study treatment death date, or data cut-off date, whichever was earlier (maximum up to 28.8 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tucatinib+Trastuzumab (Cohort 1)9/11 (81.8%)5/11 (45.5%)10/11 (90.9%)
Tucatinib+Trastuzumab (Cohort 2)22/31 (71%)11/31 (35.5%)30/31 (96.8%)
Tucatinib+Trastuzumab (Cohort 3)22/30 (73.3%)13/30 (43.3%)29/30 (96.7%)
Tucatinib+Trastuzumab (Cohort 4)17/25 (68%)9/25 (36%)23/25 (92%)
Tucatinib+Trastuzumab (Cohort 5)6/12 (50%)2/12 (16.7%)12/12 (100%)
Tucatinib+Trastuzumab (Cohort 6)21/31 (67.7%)9/31 (29%)29/31 (93.5%)
Tucatinib+Trastuzumab (Cohort 7)10/13 (76.9%)7/13 (53.8%)13/13 (100%)
Tucatinib+Trastuzumab+ Fulvestrant (Cohort 8)11/31 (35.5%)8/31 (25.8%)31/31 (100%)
Tucatinib+Trastuzumab (Cohort 9)25/33 (75.8%)14/33 (42.4%)30/33 (90.9%)
Most frequent serious events
Showing 10 of 94
Most frequent serious events
EventTucatinib+Trastuzumab (Cohort 1)Tucatinib+Trastuzumab (Cohort 2)Tucatinib+Trastuzumab (Cohort 3)Tucatinib+Trastuzumab (Cohort 4)Tucatinib+Trastuzumab (Cohort 5)Tucatinib+Trastuzumab (Cohort 6)Tucatinib+Trastuzumab (Cohort 7)Tucatinib+Trastuzumab+ Fulvestrant (Cohort 8)Tucatinib+Trastuzumab (Cohort 9)
Acute kidney injuryRenal and urinary disorders0/111/311/303/250/120/310/131/312/33
Abdominal painGastrointestinal disorders1/110/310/300/250/121/311/130/312/33
ConstipationGastrointestinal disorders1/110/310/300/250/120/310/130/310/33
EnteritisGastrointestinal disorders1/110/310/300/250/120/310/130/310/33
Intestinal obstructionGastrointestinal disorders1/110/310/301/250/121/310/130/310/33
Small intestinal obstructionGastrointestinal disorders1/111/310/300/250/120/310/130/310/33
DyspnoeaRespiratory, thoracic and mediastinal disorders1/110/310/300/250/120/310/130/310/33
Laryngeal haemorrhageRespiratory, thoracic and mediastinal disorders1/110/310/300/250/120/310/130/310/33
AnaemiaBlood and lymphatic system disorders0/110/310/300/251/120/310/130/310/33
Atrial flutterCardiac disorders0/110/310/300/251/120/310/130/310/33
Most frequent other events
Showing 10 of 152
Most frequent other events
EventTucatinib+Trastuzumab (Cohort 1)Tucatinib+Trastuzumab (Cohort 2)Tucatinib+Trastuzumab (Cohort 3)Tucatinib+Trastuzumab (Cohort 4)Tucatinib+Trastuzumab (Cohort 5)Tucatinib+Trastuzumab (Cohort 6)Tucatinib+Trastuzumab (Cohort 7)Tucatinib+Trastuzumab+ Fulvestrant (Cohort 8)Tucatinib+Trastuzumab (Cohort 9)
DiarrhoeaGastrointestinal disorders7/1116/3112/3013/259/1213/319/1319/3112/33
NauseaGastrointestinal disorders6/1113/316/306/253/127/314/1311/319/33
VomitingGastrointestinal disorders5/1112/314/302/252/127/314/139/3110/33
Blood creatinine increasedInvestigations5/117/318/305/252/129/313/133/317/33
PyrexiaGeneral disorders3/114/3113/304/251/1213/311/136/3110/33
ChillsGeneral disorders4/115/317/307/252/1211/314/136/3113/33
FatigueGeneral disorders2/1112/314/304/252/125/315/136/317/33
Infusion related reactionInjury, poisoning and procedural complications3/116/318/308/254/1212/313/138/3112/33
Alanine aminotransferase increasedInvestigations4/114/318/305/253/127/313/134/318/33
Weight decreasedInvestigations4/113/311/305/251/123/311/132/311/33

Baseline characteristics

The Full Analysis Set (FAS) included all participants who were enrolled in the study and received any amount of study treatment.

Age, Continuous
Age, Continuous(Years)Tucatinib+Trastuzumab (Cohort 1)Tucatinib+Trastuzumab (Cohort 2)Tucatinib+Trastuzumab (Cohort 3)Tucatinib+Trastuzumab (Cohort 4)Tucatinib+Trastuzumab (Cohort 5)Tucatinib+Trastuzumab (Cohort 6)Tucatinib+Trastuzumab (Cohort 7)Tucatinib+Trastuzumab+ Fulvestrant (Cohort 8)Tucatinib+Trastuzumab (Cohort 9)Total
Mean53.6 ± 15.367.6 ± 7.466.4 ± 10.167.5 ± 11.669.7 ± 11.162.7 ± 10.771.3 ± 9.561.3 ± 10.363.8 ± 10.564.9 ± 11.0
Sex: Female, Male
Sex: Female, Male(Participants)Tucatinib+Trastuzumab (Cohort 1)Tucatinib+Trastuzumab (Cohort 2)Tucatinib+Trastuzumab (Cohort 3)Tucatinib+Trastuzumab (Cohort 4)Tucatinib+Trastuzumab (Cohort 5)Tucatinib+Trastuzumab (Cohort 6)Tucatinib+Trastuzumab (Cohort 7)Tucatinib+Trastuzumab+ Fulvestrant (Cohort 8)Tucatinib+Trastuzumab (Cohort 9)Total
Female113115642063116140
Male001519811701777
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Tucatinib+Trastuzumab (Cohort 1)Tucatinib+Trastuzumab (Cohort 2)Tucatinib+Trastuzumab (Cohort 3)Tucatinib+Trastuzumab (Cohort 4)Tucatinib+Trastuzumab (Cohort 5)Tucatinib+Trastuzumab (Cohort 6)Tucatinib+Trastuzumab (Cohort 7)Tucatinib+Trastuzumab+ Fulvestrant (Cohort 8)Tucatinib+Trastuzumab (Cohort 9)Total
Hispanic or Latino01121202110
Not Hispanic or Latino1129261782592430179
Unknown or Not Reported01363445228
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Tucatinib+Trastuzumab (Cohort 1)Tucatinib+Trastuzumab (Cohort 2)Tucatinib+Trastuzumab (Cohort 3)Tucatinib+Trastuzumab (Cohort 4)Tucatinib+Trastuzumab (Cohort 5)Tucatinib+Trastuzumab (Cohort 6)Tucatinib+Trastuzumab (Cohort 7)Tucatinib+Trastuzumab+ Fulvestrant (Cohort 8)Tucatinib+Trastuzumab (Cohort 9)Total
American Indian or Alaska Native0000000000
Asian6923532011123101
Native Hawaiian or Other Pacific Islander0000000000
Black or African American14120011010
White41831265715878
More than one race0000000000
Unknown or Not Reported00363644228
09

Study locations

108 sites

Showing the first 100 of 108 sites across 8 countries. Choose a country and city above to see the rest.

10

References and documents

Publications

  • Okines AFC, Curigliano G, Mizuno N, Oh DY, Rorive A, Soliman H, Takahashi S, Bekaii-Saab T, Burkard ME, Chung KY, Debruyne PR, Fox JR, Gambardella V, Gil-Martin M, Hamilton EP, Monk BJ, Nakamura Y, Nguyen D, O'Malley DM, Olawaiye AB, Pothuri B, Reck M, Sudo K, Sunakawa Y, Van Marcke C, Yu EY, Ramos J, Tan S, Bieda M, Stinchcombe TE, Pohlmann PR. Tucatinib and trastuzumab in HER2-mutated metastatic breast cancer: a phase 2 basket trial. Nat Med. 2025 Mar;31(3):909-916. doi: 10.1038/s41591-024-03462-0. Epub 2025 Jan 17. PubMed 39825152 ↗
  • Nakamura Y, Mizuno N, Sunakawa Y, Canon JL, Galsky MD, Hamilton E, Hayashi H, Jerusalem G, Kim ST, Lee KW, Kankeu Fonkoua LA, Monk BJ, Nguyen D, Oh DY, Okines A, O'Malley DM, Pohlmann P, Reck M, Shin SJ, Sudo K, Takahashi S, Van Marcke C, Yu EY, Groisberg R, Ramos J, Tan S, Stinchcombe TE, Bekaii-Saab T. Tucatinib and Trastuzumab for Previously Treated Human Epidermal Growth Factor Receptor 2-Positive Metastatic Biliary Tract Cancer (SGNTUC-019): A Phase II Basket Study. J Clin Oncol. 2023 Dec 20;41(36):5569-5578. doi: 10.1200/JCO.23.00606. Epub 2023 Sep 26. PubMed 37751561 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2021 to primary completion in Nov 2023, 33 months.

Results were first posted in Nov 2024, 1 year after primary completion.

Of 50 industry-sponsored phase 2 interventional studies under Uterine Cervical Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 46. This study's 33 months is close to that.

Counting every sponsor, half of 204 studies reached it within 42 months; a quarter within 29 and three quarters within 77.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 1, 2020
First posted
Oct 8, 2020
StartActual
Jan 11, 2021
Primary completionActual
Nov 1, 2023
CompletionEst.
Dec 31, 2026
Results first posted
Nov 13, 2024
Last update
Aug 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT04579380
Responsible party
Sponsor
First posted
Oct 8, 2020
Start date
Jan 11, 2021
Primary completion
Nov 1, 2023
Completion
Dec 31, 2026 (estimated)
Results posted
Nov 13, 2024
Last update
Aug 21, 2026

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tucatinib

Start the discussion